psychotherapies in general? Broader utilization of this set of measures in standard clinical trials will help unravel this.
Limited data have been accumulated in this regard. Levy et al.(2006) , in a randomized controlled trial (RCT) of 90 patients with borderline personality disorder treated either with dialectical behavioral therapy (DBT), transference-focused psychotherapy (TFP), or supportive psychotherapy (ST), found significantly greater change in RF in the TFP condition relative to the other groups. Bouchard et al. (2008) have demonstrated that low RF scores on 73 Adult Attachment Interviews predicted the presence of Axis I or II disorders. Does an increase in RF then correlate with a diminution of Axis I symptomatology? A cogent research strategy might examine changes in patients' reflective capacities over the course of psychotherapeutic or psychopharmacological treatments geared to specific Axis I or II disorders. Do improvements in RF precede symptomatic improvement? Does an improvement in reflective capacity follow symptomatic change, and thus not mediate it, yet nonetheless contribute to overall improvement or to relapse prevention on follow-up? (see Figure 1 ).
Psychodynamic psychotherapies tested in randomized controlled trials are usually symptom-or diagnosis-specific, focused on helping patients understand the psychological underpinnings of their illness. In an effort to refine the RF measure to look specifically at individuals' reflective capacities about their personal symptomatic affective experience, we developed symptom-specific RF measures. Within brief dynamic therapies, it is most likely that reflective changes will center on this aspect of patients' mental lives. Potential mediators are measured before the therapy, within the therapy yet before symptomatic changes are anticipated, and at termination. Changes in the potential mediator are assessed in relation to changes in the primary outcome measure (psychiatric symptoms). To be found a true mediator, a variable must change consistently before symptomatic improvement occurs, and symptomatic improvement cannot occur without change in the mediator.
Moderators. Patient pre-treatment attributes that affect degree of response (as tracked
by the primary outcome measure) to a specific therapy. Potential moderators are measured before treatment. Presence or absence of the moderator variable significantly predicts degree of response to the therapy, either positively or negatively.
All mediator and moderator studies are viewed as preliminary data for the design of future studies, not as constituting a level of evidence that without further evaluation could permit treatment recommendations (Kraemer et al. 2002) ------------------------------------------------------------------------------------------------------

Studies of Symptom-Specific RF
Panic disorder. A measure of symptom-specific RF was piloted (Rudden et al. 2006 ) within a randomized controlled trial (Milrod et al.2007 ) of panic-focused psychodynamic psychotherapy (PFPP; Milrod et al. 1997) , as compared with applied relaxation therapy (ART; Cerney, Vermilyea, and Barlow 1984) . The scale, based on the RF scoring system, is scored from a brief, semistructured interview. Though the sample was quite small since the pilot study began during year 2 of the RCT (N = 26; PFPP cell, n = 18; ART, n = 8), there were promising findings. The panic-specific RF scale (PSRF) was found to be reliable (20 interviews, 2 raters, ICC = 0.86), and PSRF improved significantly in the psychodynamic therapy group (Z = -2.116, p = .03), while it worsened after ART (Z = -12.04, p = .04). Between -group difference post-treatment was quite significant (Z = -2.75, p = .006). PSRF is now is now being tested as a potential mediator of psychodynamic change in a two-site RCT of PFPP, ART, and cognitive-behavior therapy (CBT); Barbara Milrod and Jacques Barber, co-PIs. RF is being tested as a moderator of PFPP (Figure 2) . interventions have yet to receive broad investigation. Because IPT for PTSD focuses on helping patients reflect on the thoughts, feelings, and intentions of others affected by patients' symptomatology and to improve interpersonal relationships, we hypothesize that IPT will increase patients' RF. We hypothesize also that increased general and symptomspecific RF will mediate symptomatic improvement in IPT. RF is not expected to change meaningfully in the PE and Relaxation conditions. Data analysis is planned to evaluate symptom-specific RF at three time intervals (weeks 0, 4, and 14) to test mediator status.
MDD
RCT of IPT vs. BRT for MDD. PIs: Fredrik Falkenström and Rolf Holmqvist, Linköping University, Sweden.
Patients randomized to either IPT or BRT will be scored for RF and symptom-specific RF before treatment, at termination and at follow-up one and two years after termination. RF and symptom-specific RF will be evaluated as moderators and as mechanisms of change in the treatments.
Discussion
There are several advantages in using symptom-specific RF measures in psychotherapy outcome studies.
1. Symptom-specific RF makes it possible to import a well-researched, reliable, and valid set of psychoanalytic measures for a developmentally derived ego capacity, RF, to standard outcome research methodology. While assessing a subject's capacity to reflect on his or her psychological processes as they connect to a particular symptom, it nonetheless maintains the complexity of the original RF concept.
2. Symptom-specific RF corrects for the tendency of general RF to measure a subject's reflections on the motivations and behavior of others more accurately than one's own (Safran and Muran 2000) .
3. Symptom-specific RF is scored from a brief, easily administered interview, facilitating its incorporation into RCTs.
4. The PSRF measure has been shown to have excellent interrater reliability in two different settings.
5. In the pilot PSRF study significant PSRF improvements were noted in the PFPP group.
6. Symptom-specific RF can easily be used with the revised brief RF interview (Rudden et al. 2006 ).
Despite these advantages of symptom-specific RF, however, there are disadvantages to its use.
1. In the pilot PSRF study, no correlation was found between changes in the primary outcome measure, the Panic Disorder Severity Scale (PDSS; Shear et al. 1997) and changes in PSRF after PFPP (rho = -.03, p = .29). The sample was likely too small to accurately measure this.
2. Because of the small sample in the pilot study, rigorous psychometrics gauging the validity of the measure have not been performed.
Conclusion
Symptom-specific RF is a measure of psychological change currently being studied as a potential mediator, as a potential moderator, and as a correlate of symptomatic change in three RCTs. These measures are based on the concepts, scale, and scoring system for reflective functioning, which have been extensively researched and validated, and can be scored with excellent interrater reliability. The centrality of symptom-specific RF in the domain of standard psychotherapy research remains to be determined.
